Kynurenic Acid
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Kynurenic Acid
- DrugBank Accession Number
- DB11937
- Background
Kynurenic Acid is under investigation in clinical trial NCT02340325 (FS2 Safety and Tolerability Study in Healthy Volunteers).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 189.1675
Monoisotopic: 189.042593095 - Chemical Formula
- C10H7NO3
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAryl hydrocarbon receptor Not Available Humans UG-protein coupled receptor 35 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds show 4 more
- Substituents
- Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carboxylic acid / Carboxylic acid derivative / Dihydroquinoline / Dihydroquinolone / Heteroaromatic compound / Hydrocarbon derivative / Monocarboxylic acid or derivatives show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- monohydroxyquinoline, quinolinemonocarboxylic acid (CHEBI:18344)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H030S2S85J
- CAS number
- 492-27-3
- InChI Key
- HCZHHEIFKROPDY-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H7NO3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5H,(H,11,12)(H,13,14)
- IUPAC Name
- 4-oxo-1,4-dihydroquinoline-2-carboxylic acid
- SMILES
- OC(=O)C1=CC(=O)C2=CC=CC=C2N1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000715
- KEGG Compound
- C01717
- PubChem Compound
- 3845
- PubChem Substance
- 347828264
- ChemSpider
- 3712
- BindingDB
- 81975
- ChEBI
- 18344
- ChEMBL
- CHEMBL299155
- ZINC
- ZINC000008584773
- PDBe Ligand
- KYA
- PDB Entries
- 3av7 / 3wx9 / 6u7a
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Cicatrix / Hypertrophic Cicatrix / Keloids Scars 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.954 mg/mL ALOGPS logP 1.16 ALOGPS logP 1.58 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 4.47 Chemaxon pKa (Strongest Basic) -4.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 66.4 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 52.32 m3·mol-1 Chemaxon Polarizability 18.05 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 144.3566919 predictedDarkChem Lite v0.1.0 [M-H]- 140.9068014 predictedDarkChem Standard v0.1.0 [M-H]- 144.2444919 predictedDarkChem Lite v0.1.0 [M-H]- 144.1502919 predictedDarkChem Lite v0.1.0 [M-H]- 130.21909 predictedDeepCCS 1.0 (2019) [M+H]+ 145.7975919 predictedDarkChem Lite v0.1.0 [M+H]+ 142.8516193 predictedDarkChem Standard v0.1.0 [M+H]+ 145.6542919 predictedDarkChem Lite v0.1.0 [M+H]+ 145.4614919 predictedDarkChem Lite v0.1.0 [M+H]+ 132.69075 predictedDeepCCS 1.0 (2019) [M+Na]+ 144.4689919 predictedDarkChem Lite v0.1.0 [M+Na]+ 165.6349823 predictedDarkChem Standard v0.1.0 [M+Na]+ 144.4555919 predictedDarkChem Lite v0.1.0 [M+Na]+ 141.10371 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsAryl hydrocarbon receptor
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transcription regulatory region dna binding
- Specific Function
- Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
- Gene Name
- AHR
- Uniprot ID
- P35869
- Uniprot Name
- Aryl hydrocarbon receptor
- Molecular Weight
- 96146.705 Da
References
- DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH: Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 2010 May;115(1):89-97. doi: 10.1093/toxsci/kfq024. Epub 2010 Jan 27. [Article]
2. DetailsG-protein coupled receptor 35
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- G-protein coupled receptor activity
- Specific Function
- Acts as a receptor for kynurenic acid, an intermediate in the tryptophan metabolic pathway. The activity of this receptor is mediated by G-proteins that elicit calcium mobilization and inositol pho...
- Gene Name
- GPR35
- Uniprot ID
- Q9HC97
- Uniprot Name
- G-protein coupled receptor 35
- Molecular Weight
- 34071.89 Da
References
- Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME: Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and beta-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22. [Article]
Drug created at October 20, 2016 21:02 / Updated at June 12, 2020 16:53